Top

Published in:

01-01-2015 | Laboratory Investigation

EGCG inhibits properties of glioma stem-like cells and synergizes with temozolomide through downregulation of P-glycoprotein inhibition

Authors: Yong Zhang, Shao-Xiang Wang, Ji-Wei Ma, Hai-Ying Li, Jie-Cheng Ye, Si-Ming Xie, Bin Du, Xue-Yun Zhong

Published in: Journal of Neuro-Oncology | Issue 1/2015

Abstract

Rational: Combination therapy to inhibit cancer stem cells may have important clinical implications. Here, we examine the molecular mechanisms by which epigallocatechin gallate (EGCG), a bioactive polyphenol in green tea, inhibits the stem cell characteristics of glioma stem-like cells (GSLCs) and synergizes with temozolomide (TMZ), a DNA-methylating agent commonly used as first-line chemotherapy in gliomas. GSLCs were enriched from the human glioblastoma cell line U87 using neurosphere culture. Cells were analyzed using flow cytometry, quantitative PCR, and western blotting. Compared to U87 cells, a higher percentage of U87 GSLCs remained in the G0/G1 phase, with downregulation of the cell-cycle protein CylinD1 and overexpression of stem cell markers CD133 and ALDH1. The drug-resistance gene ABCB1 (but not ABCG2 or MGMT) also showed high mRNA and protein expression. The resistance index of U87 GSLCs against TMZ and carmustine (BCNU) was 3.0 and 16.8, respectively. These results indicate that U87 GSLCs possess neural stem cell and drug-resistance properties. Interestingly, EGCG treatment inhibited cell viability, neurosphere formation, and migration in this cell model. EGCG also induced apoptosis, downregulation of p-Akt and Bcl-2, and cleaving PARP in a dose-dependent manner. Importantly, EGCG treatment significantly downregulated P-glycoprotein expression but not that of ABCG2 or MGMT and simultaneously enhanced sensitivity to TMZ. Our study demonstrates that the use of EGCG alone or in combination with TMZ may be an effective therapeutic strategy for glioma.

Available only for authorised users

Sarkaria JN, Kitange GJ, James CD, Plummer R, Calvert H, Weller M, Wick W (2008) Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res 14:2900–2908. doi:10.1158/1078-0432.CCR-07-1719 PubMedCentralPubMedCrossRef

Sai K, Yang QY, Shen D, Chen ZP (2013) Chemotherapy for gliomas in mainland China: an overview. Oncol Lett 5:1448–1452. doi:10.3892/ol.2013.1264 PubMedCentralPubMed

Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, Fiocco R, Foroni C, Dimeco F, Vescovi A (2004) Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 64:7011–7021. doi:10.1158/0008-5472.CAN-04-1364 PubMedCrossRef

Christmann M, Verbeek B, Roos WP, Kaina B (2011) O(6)-Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors: enzyme activity, promoter methylation and immunohistochemistry. Biochim Biophys Acta 1816:179–190. doi:10.1016/j.bbcan.2011.06.002 PubMed

Nakai E, Park K, Yawata T, Chihara T, Kumazawa A, Nakabayashi H, Shimizu K (2009) Enhanced MDR1 expression and chemoresistance of cancer stem cells derived from glioblastoma. Cancer Invest 27:901–908. doi:10.3109/07357900801946679 PubMedCrossRef

Yin BB, Wu SJ, Zong HJ, Ma BJ, Cai D (2011) Preliminary screening and identification of stem cell-like sphere clones in a gallbladder cancer cell line GBC-SD. J Zhejiang Univ Sci B 12:256–263. doi:10.1631/jzus.B1000303 PubMedCentralPubMedCrossRef

Imai Y, Tsukahara S, Asada S, Sugimoto Y (2004) Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res 64:4346–4352. doi:10.1158/0008-5472.CAN-04-0078 PubMedCrossRef

Shi Z, Liang YJ, Chen ZS, Wang XW, Wang XH, Ding Y, Chen LM, Yang XP, Fu LW (2006) Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo. Cancer Biol Ther 5:39–47PubMedCrossRef

Vlachostergios PJ, Hatzidaki E, Befani CD, Liakos P, Papandreou CN (2013) Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner. Invest New Drugs. doi:10.1007/s10637-013-9968-1 PubMed

10.

Singh BN, Shankar S, Srivastava RK (2011) Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol 82:1807–1821. doi:10.1016/j.bcp.2011.07.093 PubMedCentralPubMedCrossRef

11.

Shankar S, Ganapathy S, Srivastava RK (2007) Green tea polyphenols: biology and therapeutic implications in cancer. Front Biosci 12:4881–4899PubMedCrossRef

12.

Chen H, Landen CN, Li Y, Alvarez RD, Tollefsbol TO (2013) Epigallocatechin gallate and sulforaphane combination treatment induce apoptosis in paclitaxel-resistant ovarian cancer cells through hTERT and Bcl-2 down-regulation. Exp Cell Res 319:697–706. doi:10.1016/j.yexcr.2012.12.026 PubMedCentralPubMedCrossRef

13.

Sadava D, Whitlock E, Kane SE (2007) The green tea polyphenol, epigallocatechin-3-gallate inhibits telomerase and induces apoptosis in drug-resistant lung cancer cells. Biochem Biophys Res Commun 360:233–237. doi:10.1016/j.bbrc.2007.06.030 PubMedCrossRef

14.

Farabegoli F, Papi A, Bartolini G, Ostan R, Orlandi M (2010) (-)-Epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line. Phytomedicine 17:356–362. doi:10.1016/j.phymed.2010.01.001 PubMedCrossRef

15.

Huang HY, Niu JL, Zhao LM, Lu YH (2011) Reversal effect of 2′,4′-dihydroxy-6′-methoxy-3′,5′-dimethylchalcone on multi-drug resistance in resistant human hepatocellular carcinoma cell line BEL-7402/5-FU. Phytomedicine 18:1086–1092. doi:10.1016/j.phymed.2011.04.001 PubMedCrossRef

16.

Burnette WN (1981) “Western blotting”: electrophoretic transfer of proteins from sodium dodecyl sulfate–polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal Biochem 112:195–203PubMedCrossRef

17.

Wan F, Zhang S, Xie R, Gao B, Campos B, Herold-Mende C, Lei T (2010) The utility and limitations of neurosphere assay, CD133 immunophenotyping and side population assay in glioma stem cell research. Brain Pathol 20:877–889. doi:10.1111/j.1750-3639.2010.00379.x PubMed

18.

Chaichana K, Zamora-Berridi G, Camara-Quintana J, Quinones-Hinojosa A (2006) Neurosphere assays: growth factors and hormone differences in tumor and nontumor studies. Stem Cells 24:2851–2857. doi:10.1634/stemcells.2006-0399 PubMedCrossRef

19.

Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang DG (2005) Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2− cancer cells are similarly tumorigenic. Cancer Res 65:6207–6219. doi:10.1158/0008-5472.CAN-05-0592 PubMedCrossRef

20.

Venezia TA, Merchant AA, Ramos CA, Whitehouse NL, Young AS, Shaw CA, Goodell MA (2004) Molecular signatures of proliferation and quiescence in hematopoietic stem cells. PLoS Biol 2:e301. doi:10.1371/journal.pbio.0020301 PubMedCentralPubMedCrossRef

21.

Persano L, Rampazzo E, Basso G, Viola G (2013) Glioblastoma cancer stem cells: role of the microenvironment and therapeutic targeting. Biochem Pharmacol 85:612–622. doi:10.1016/j.bcp.2012.10.001 PubMedCrossRef

22.

Mori H, Ninomiya K, Kino-oka M, Shofuda T, Islam MO, Yamasaki M, Okano H, Taya M, Kanemura Y (2006) Effect of neurosphere size on the growth rate of human neural stem/progenitor cells. J Neurosci Res 84:1682–1691. doi:10.1002/jnr.21082 PubMedCrossRef

23.

Tabatabai G, Weller M (2011) Glioblastoma stem cells. Cell Tissue Res 343:459–465. doi:10.1007/s00441-010-1123-0 PubMedCrossRef

24.

Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63:5821–5828PubMed

25.

Deng S, Yang X, Lassus H, Liang S, Kaur S, Ye Q, Li C, Wang LP, Roby KF, Orsulic S, Connolly DC, Zhang Y, Montone K, Butzow R, Coukos G, Zhang L (2010) Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One 5:e10277. doi:10.1371/journal.pone.0010277 PubMedCentralPubMedCrossRef

26.

Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1:555–567. doi:10.1016/j.stem.2007.08.014 PubMedCentralPubMedCrossRef

27.

Li T, Su Y, Mei Y, Leng Q, Leng B, Liu Z, Stass SA, Jiang F (2010) ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients’ outcome. Lab Invest 90:234–244. doi:10.1038/labinvest.2009.127 PubMedCentralPubMedCrossRef

28.

Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, Fields JZ, Wicha MS, Boman BM (2009) Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 69:3382–3389. doi:10.1158/0008-5472.CAN-08-4418 PubMedCentralPubMedCrossRef

29.

Zang Y, Yu LF, Nan FJ, Feng LY, Li J (2009) AMP-activated protein kinase is involved in neural stem cell growth suppression and cell cycle arrest by 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside and glucose deprivation by down-regulating phospho-retinoblastoma protein and cyclin D. J Biol Chem 284:6175–6184. doi:10.1074/jbc.M806887200 PubMedCrossRef

30.

Zhao S, Liu H, Liu Y, Wu J, Wang C, Hou X, Chen X, Yang G, Zhao L, Che H, Bi Y, Wang H, Peng F, Ai J (2013) miR-143 inhibits glycolysis and depletes stemness of glioblastoma stem-like cells. Cancer Lett 333:253–260. doi:10.1016/j.canlet.2013.01.039 PubMedCrossRef

31.

Lin CH, Shen YA, Hung PH, Yu YB, Chen YJ (2012) Epigallocathechin gallate, polyphenol present in green tea, inhibits stem-like characteristics and epithelial-mesenchymal transition in nasopharyngeal cancer cell lines. BMC Complement Altern Med 12:201. doi:10.1186/1472-6882-12-201 PubMedCentralPubMedCrossRef

32.

Lee SH, Nam HJ, Kang HJ, Kwon HW, Lim YC (2013) Epigallocatechin-3-gallate attenuates head and neck cancer stem cell traits through suppression of Notch pathway. Eur J Cancer. doi:10.1016/j.ejca.2013.06.025

33.

Chen D, Pamu S, Cui Q, Chan TH, Dou QP (2012) Novel epigallocatechin gallate (EGCG) analogs activate AMP-activated protein kinase pathway and target cancer stem cells. Bioorg Med Chem 20:3031–3037. doi:10.1016/j.bmc.2012.03.002 PubMedCentralPubMedCrossRef

34.

Tang SN, Fu J, Nall D, Rodova M, Shankar S, Srivastava RK (2012) Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics. Int J Cancer 131:30–40. doi:10.1002/ijc.26323 PubMedCentralPubMedCrossRef

35.

Tang SN, Singh C, Nall D, Meeker D, Shankar S, Srivastava RK (2010) The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition. J Mol Signal 5:14. doi:10.1186/1750-2187-5-14 PubMedCentralPubMedCrossRef

36.

Van Aller GS, Carson JD, Tang W, Peng H, Zhao L, Copeland RA, Tummino PJ, Luo L (2011) Epigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase/mTOR inhibitor. Biochem Biophys Res Commun 406:194–199. doi:10.1016/j.bbrc.2011.02.010 PubMedCrossRef

37.

Premkumar DR, Jane EP, DiDomenico JD, Vukmer NA, Agostino NR, Pollack IF (2012) ABT-737 synergizes with bortezomib to induce apoptosis, mediated by Bid cleavage, Bax activation, and mitochondrial dysfunction in an Akt-dependent context in malignant human glioma cell lines. J Pharmacol Exp Ther 341:859–872. doi:10.1124/jpet.112.191536 PubMedCentralPubMedCrossRef

38.

Chen NG, Lu CC, Lin YH, Shen WC, Lai CH, Ho YJ, Chung JG, Lin TH, Lin YC, Yang JS (2011) Proteomic approaches to study epigallocatechin gallate-provoked apoptosis of TSGH-8301 human urinary bladder carcinoma cells: roles of AKT and heat shock protein 27-modulated intrinsic apoptotic pathways. Oncol Rep 26:939–947. doi:10.3892/or.2011.1377 PubMed

39.

Liu D, Li P, Song S, Liu Y, Wang Q, Chang Y, Wu Y, Chen J, Zhao W, Zhang L, Wei W (2012) Pro-apoptotic effect of epigallo-catechin-3-gallate on B lymphocytes through regulating BAFF/PI3 K/Akt/mTOR signaling in rats with collagen-induced arthritis. Eur J Pharmacol 690:214–225. doi:10.1016/j.ejphar.2012.06.026 PubMedCrossRef

40.

Li C, Zhou C, Wang S, Feng Y, Lin W, Lin S, Wang Y, Huang H, Liu P, Mu YG, Shen X (2011) Sensitization of glioma cells to tamoxifen-induced apoptosis by Pl3-kinase inhibitor through the GSK-3beta/beta-catenin signaling pathway. PLoS One 6:e27053. doi:10.1371/journal.pone.0027053 PubMedCentralPubMedCrossRef

41.

Manero F, Gautier F, Gallenne T, Cauquil N, Gree D, Cartron PF, Geneste O, Gree R, Vallette FM, Juin P (2006) The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death. Cancer Res 66:2757–2764. doi:10.1158/0008-5472.CAN-05-2097 PubMedCrossRef

42.

Bleau AM, Huse JT, Holland EC (2009) The ABCG2 resistance network of glioblastoma. Cell Cycle 8:2936–2944PubMedCrossRef

43.

Liu L, Gerson SL (2006) Targeted modulation of MGMT: clinical implications. Clin Cancer Res 12:328–331. doi:10.1158/1078-0432.CCR-05-2543 PubMedCrossRef

44.

Chahal M, Xu Y, Lesniak D, Graham K, Famulski K, Christensen JG, Aghi M, Jacques A, Murray D, Sabri S, Abdulkarim B (2010) MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib. Neuro Oncol 12:822–833. doi:10.1093/neuonc/noq017 PubMedCentralPubMedCrossRef

45.

Ryu CH, Yoon WS, Park KY, Kim SM, Lim JY, Woo JS, Jeong CH, Hou Y, Jeun SS (2012) Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells. J Biomed Biotechnol 2012:987495. doi:10.1155/2012/987495 PubMedCentralPubMedCrossRef

46.

Chen TC, Wang W, Golden EB, Thomas S, Sivakumar W, Hofman FM, Louie SG, Schonthal AH (2011) Green tea epigallocatechin gallate enhances therapeutic efficacy of temozolomide in orthotopic mouse glioblastoma models. Cancer Lett 302:100–108. doi:10.1016/j.canlet.2010.11.008 PubMedCrossRef

47.

Qian F, Wei D, Zhang Q, Yang S (2005) Modulation of P-glycoprotein function and reversal of multidrug resistance by (−)-epigallocatechin gallate in human cancer cells. Biomed Pharmacother 59:64–69. doi:10.1016/j.biopha.2005.01.002 PubMedCrossRef

48.

Weksler BB, Subileau EA, Perriere N, Charneau P, Holloway K, Leveque M, Tricoire-Leignel H, Nicotra A, Bourdoulous S, Turowski P, Male DK, Roux F, Greenwood J, Romero IA, Couraud PO (2005) Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J 19:1872–1874. doi:10.1096/fj.04-3458fje PubMed

49.

Jodoin J, Demeule M, Beliveau R (2002) Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols. Biochim Biophys Acta 1542:149–159PubMedCrossRef

50.

Riganti C, Salaroglio IC, Caldera V, Campia I, Kopecka J, Mellai M, Annovazzi L, Bosia A, Ghigo D, Schiffer D (2013) Temozolomide downregulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a/glycogen synthase-3 kinase/beta-catenin pathway. Neuro Oncol. doi:10.1093/neuonc/not104 PubMedCentralPubMed

Title: EGCG inhibits properties of glioma stem-like cells and synergizes with temozolomide through downregulation of P-glycoprotein inhibition
Authors: Yong Zhang
Shao-Xiang Wang
Ji-Wei Ma
Hai-Ying Li
Jie-Cheng Ye
Si-Ming Xie
Bin Du
Xue-Yun Zhong
Publication date: 01-01-2015
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 1/2015
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-014-1604-1

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

EGCG inhibits properties of glioma stem-like cells and synergizes with temozolomide through downregulation of P-glycoprotein inhibition

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2015

Phosphorylation of AKT induced by phosphorylated Hsp27 confers the apoptosis-resistance in t-AUCB-treated glioblastoma cells in vitro

Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma

Quantitative analysis of tumor volume reduction after three-dimensional conformal radiation therapy for intracranial meningiomas

Expression of astrocyte elevated gene-1 (AEG-1) in human meningiomas and its roles in cell proliferation and survival

Familial gliomas: cases in two pairs of brothers

Tight regulation between cell survival and programmed cell death in GBM stem-like cells by EGFR/GSK3b/PP2A signaling